CORELINE SOFT Participates in ACTI 2023... Asian Medical AI Experts Invited as Speakers
Shares the latest research results with AVIEW at the luncheon symposium
Exhibits chest diagnosis solution, AVIEW LCS and more
ACTI (Asian Congress of Thoracic Imaging) aims to reduce the medical technology gap in Asia, and focus on sharing and collaboration of research results by specialists in thoracic imaging to lay the ground for non-discriminatory medical services in the region. It hosts conferences in the Asian member countries in rotation to improve accessibility since it was first held in Seoul in 2006, and now it is back in Seoul in 2023. 400 experts from 20 countries, including Europe and USA, will attend to share the latest research findings and technology trends. ACTI 2023 co-hosts with the Korean Society of Thoracic Radiology (KSTR) for three days from June 15 to 17 at the Grand Walkerhill Hotel in Seoul, South Korea.
Coreline will share globally supplied AI solutions at the booth and provide ideas on how to effectively use its AI solution: AVIEW. Invited speakers will inform the audience of their experience and the effectiveness of AVIEW in the clinical environment. The main theme is ‘Experience of AI Solutions for Clinical Application’.
Three speakers are Professor Gong Yong Jin of Jeonbuk National University Hospital presenting ‘Clinical application of AI in chest disease Using AVIEW AI Solution’, Professor Li Zhu, at Ningxia Medical University General Hospital, China, on ‘Radiology on Major Thoracic Chronic Diseases, Research Status’, and ‘Treatment Response Evaluation by Computed Tomography Pulmonary Vasculature Analysis in Patients with Chronic Thromboembolic Pulmonary Hypertension’' by Doctor Yeun-Chung Chang, Professor at National Taiwan University Hospital. CMO of Coreline, Sanghyun Paik, the clinical professor at Hanyang University Seoul Hospital serves as the moderator. The luncheon session is scheduled from 11:40 a.m. to 12:40 p.m. on Friday, June 16.
Coreline looks forward to new cooperative relationships with domestic and foreign thoracic imaging experts at the conference. Additionally, it aims to support radiologists and physicians by providing products that align with the latest medical requirements.
Coreline developed the world‘s first chest disease simultaneous diagnosis solution ’AVIEW LCS PLUS', and became the sole solution supplier to the national lung cancer screening project at home and took part in shaping the overseas lung cancer screening project in Europe. The notable overseas achievements are winning orders for the Lung Cancer Screening Project (4ITLR), the German Lung Cancer Screening Project (HANSE), and the Italian Lung Cancer Screening Project (ILSP) hosted by the European Union and participated by six European countries.
The company has recently received the US FDA 510(k) approval for the AI-based lung nodule detection solution ‘AVIEW Lung Nodule CAD’, making it the first domestic (Korean) product and the fifth in the world.
The company official said, “We are capitalizing on our proprietary technology of finding multiple abnormalities from one image source and will introduce new software products for angiography analysis, virtual bronchoscopy, fatty liver, and body fat analysis products”, concluding “We differentiate ourselves as a medical AI company assisting healthcare institutions to detect various diseases early and accurately.”
ACTI 2023: http://www.acti2023.org/
This news is a press release from the provider.
Korea Newswire is committed to verifying the transparency of providers and eliminating content errors.
You can receive press releases from this company or in industries of interest via email and RSS for free. Subscribe>
News provided byCoreline Soft